Medically reviewed by the HyaluFlow Health Editorial Team | Published: July 29, 2026 | Last Updated: August 26, 2026
Many people taking semaglutide worry when hunger becomes more noticeable after several months. That does not automatically mean the medication has stopped working.
A 60-week randomized trial found that semaglutide 2.4 mg continued to reduce measured calorie intake at weeks 20, 40, and 60, even though some early appetite effects became less pronounced. Short- and Long-term Effects of Semaglutide 2.4 mg on Energy Intake, Appetite, and Food Reward reported these findings in The American Journal of Clinical Nutrition.
Quick Answer
Semaglutide may continue supporting lower calorie intake even when you feel hungrier than you did during the first few months. In the 60-week trial, participants taking semaglutide consumed significantly fewer calories than those receiving placebo throughout follow-up.
Key Takeaways
- More hunger does not automatically mean semaglutide has stopped working.
- Measured calorie intake remained lower through week 60.
- The trial included 120 adults with overweight or obesity.
- Semaglutide reduced energy intake by about 240–292 calories during measured meals.
- Lifestyle counseling was provided alongside treatment.
Why Can Hunger Return?
Hunger is a subjective sensation, while calorie intake is a measurable behavior. These two measures can change differently during long-term treatment.
In the 60-week study, semaglutide produced stronger differences in hunger and appetite earlier in treatment. By weeks 40 and 60, several subjective appetite measures were no longer significantly different from placebo.
Yet measured energy intake remained significantly lower with semaglutide. That distinction is important: feeling hungrier does not necessarily mean eating the same amount as before treatment.
What Did the 60-Week Trial Find?
The double-blind randomized trial assigned 120 adults with overweight or obesity to weekly semaglutide 2.4 mg or placebo. Researchers assessed appetite and food reward and measured energy intake under controlled conditions at weeks 20, 40, and 60.
Compared with placebo, the semaglutide group consumed approximately 292 fewer calories at week 20, 240 fewer at week 40, and 270 fewer at week 60. The 2026 randomized controlled trial reported that reduced energy intake remained evident during longer-term treatment.
Does More Hunger Mean Treatment Failure?
Not by itself. Treatment response should be judged using the broader picture, including weight trends, eating patterns, adherence, tolerability, treatment duration, and prescribed dose.
The trial showed that semaglutide's effects were not limited to the first few weeks. Participants continued consuming fewer calories despite the decline in some subjective appetite benefits.
This does not mean every person will respond in the same way. Individual results vary, and a plateau or unexpected weight change deserves clinical review rather than guesswork.
Why Semaglutide Can Still Work
Semaglutide is a glucagon-like peptide-1 receptor agonist that influences pathways involved in appetite and food intake. Its effects can therefore extend beyond the noticeable feeling of being less hungry.
The latest trial supports this distinction by showing persistent reductions in measured energy intake even after some appetite ratings moved closer to placebo levels. Once-Weekly Semaglutide in Adults with Overweight or Obesity also found substantial weight loss over 68 weeks when semaglutide 2.4 mg was combined with lifestyle intervention.
What the Science Says
The strongest evidence here comes from randomized controlled trials. The 60-week study directly measured food intake, while the STEP 1 trial evaluated long-term weight outcomes in nearly 2,000 adults.
In STEP 1, average weight change at week 68 was -14.9% with semaglutide versus -2.4% with placebo. The treatment was provided alongside lifestyle intervention, so the results should not be interpreted as evidence that medication replaces healthy eating or physical activity.
Common Myths
Myth: "Feeling hungry means semaglutide stopped working."
Fact: The 60-week trial found continued reductions in measured calorie intake even when some early appetite effects had weakened.
Myth: "A weight plateau proves drug resistance."
Fact: A plateau can have multiple causes. It should be assessed alongside adherence, diet, activity, dose, treatment duration, and other factors.
Myth: "I should change my dose when hunger increases."
Fact: Dose changes should be guided by the prescribing clinician, not by appetite changes alone.
Who Should Pay Attention?
People using semaglutide for an approved medical indication should discuss persistent hunger, stalled weight loss, significant weight regain, or troublesome side effects with their healthcare professional.
The current FDA Wegovy Prescribing Information states that semaglutide for weight management is used with a reduced-calorie diet and increased physical activity and lists important contraindications and warnings.
Safety Still Matters
Common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. The FDA prescribing information also warns about pancreatitis, gallbladder disease, dehydration-related kidney injury, and severe gastrointestinal reactions.
Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should be used only under appropriate medical supervision.
A 2024 observational study reported an association between semaglutide prescriptions and nonarteritic anterior ischemic optic neuropathy, but the researchers emphasized that the study could not establish causality. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide provides the study details.
Study Limitations
The 60-week trial involved only 120 participants, and calorie intake was measured during controlled laboratory meals. Those conditions cannot perfectly reproduce everyday eating.
The participants also received lifestyle counseling, meaning the findings support semaglutide as part of a broader weight-management strategy rather than as a standalone solution.
Evidence Strength Summary
Strong: A randomized trial found significantly lower measured energy intake with semaglutide through 60 weeks.
Strong: Randomized clinical evidence supports substantial weight loss with semaglutide 2.4 mg alongside lifestyle intervention.
Moderate: Increased hunger alone does not establish that semaglutide has stopped working.
Uncertain: The possible association between semaglutide and NAION remains observational and does not prove causation.
Bottom Line
Feeling hungrier after several months does not automatically mean semaglutide has stopped working. Current randomized evidence shows that calorie intake can remain lower over 60 weeks even after some early appetite effects become less noticeable.
If hunger increases or weight loss stalls, do not change or stop the medication on your own. Review the pattern with your healthcare professional and assess the full treatment picture.
